ImmunityBio, Inc. (NASDAQ:IBRX) Holdings Increased by Barclays PLC

Barclays PLC increased its stake in ImmunityBio, Inc. (NASDAQ:IBRX) by 9.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 396,484 shares of the company’s stock after acquiring an additional 35,448 shares during the period. Barclays PLC owned approximately 0.06% of ImmunityBio worth $1,015,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in IBRX. Raymond James Financial Inc. acquired a new stake in ImmunityBio in the fourth quarter worth approximately $172,000. Capula Management Ltd bought a new stake in shares of ImmunityBio in the 4th quarter worth $154,000. Rathbones Group PLC lifted its holdings in shares of ImmunityBio by 21.8% in the fourth quarter. Rathbones Group PLC now owns 89,420 shares of the company’s stock valued at $229,000 after buying an additional 16,000 shares during the period. Wells Fargo & Company MN boosted its stake in ImmunityBio by 30.4% during the fourth quarter. Wells Fargo & Company MN now owns 138,605 shares of the company’s stock valued at $355,000 after buying an additional 32,334 shares in the last quarter. Finally, Alliancebernstein L.P. grew its holdings in ImmunityBio by 4.1% during the fourth quarter. Alliancebernstein L.P. now owns 214,030 shares of the company’s stock worth $548,000 after acquiring an additional 8,500 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Price Performance

IBRX stock opened at $2.10 on Tuesday. The company’s 50 day simple moving average is $2.76 and its 200-day simple moving average is $3.42. ImmunityBio, Inc. has a 52-week low of $2.00 and a 52-week high of $9.48. The firm has a market capitalization of $1.85 billion, a P/E ratio of -2.28 and a beta of 0.33.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.11. The business had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $8.74 million. Sell-side analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on IBRX. BTIG Research started coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price objective for the company. D. Boral Capital restated a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a report on Wednesday, April 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of ImmunityBio in a research report on Monday, April 28th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ImmunityBio currently has a consensus rating of “Buy” and an average target price of $12.19.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.